Welcome to our dedicated page for Senti Biosciences Holdings news (Ticker: SNTI), a resource for investors and traders seeking the latest updates and insights on Senti Biosciences Holdings stock.
Senti Biosciences Holdings, Inc. (SNTI) operates through Senti Bio as a clinical-stage biotechnology company developing cell and gene therapies built on a proprietary Gene Circuit synthetic biology platform. The company’s Gene Circuits are designed to program cells to sense, compute and respond to cellular environments, with applications intended to kill cancer cells, spare healthy cells, improve tissue specificity and allow post-administration control.
Recurring SNTI news centers on the Logic-Gated SENTI-202 program, an off-the-shelf CAR NK cell therapy targeting CD33 and/or FLT3 while sparing EMCN-expressing healthy cells in relapsed or refractory acute myeloid leukemia. Company updates also cover clinical and translational data presentations, peer-reviewed research on NOT-gated CAR circuits in T cells and NK cells, FDA designations for SENTI-202, financial results, conference appearances, and partnership discussions tied to the Gene Circuit platform.
Senti Biosciences reported progress in its clinical pipeline with SENTI-202 and SENTI-301A targeting hematologic and solid tumors, respectively. The company expects to file IND applications for both candidates in 2023. As of September 30, 2022, Senti Bio had $114.9 million in cash, projected to sustain operations into 2024. The third-quarter net loss was $16.6 million, or $0.38 per share, with increased R&D and G&A expenses. Notably, the company highlighted promising preclinical data at the SITC Annual Meeting, reinforcing its innovative gene circuit technology.
Senti Biosciences (Nasdaq: SNTI) announced a poster presentation at the 64th American Society of Hematology (ASH) Annual Meeting showcasing preclinical data for SENTI-202, a CAR-NK cell therapy targeting CD33 and FLT3 in acute myeloid leukemia (AML).
The presentation is scheduled for December 10, 2022, from 5:30 - 7:30 pm CST, at the Ernest N. Morial Convention Center, New Orleans. The therapy employs Logic Gating gene circuit technology to enhance targeting efficacy while protecting healthy cells. More details will be available post-presentation on Senti Bio's website.
Senti Biosciences (SNTI) announced the granting of stock options for 200,200 shares to nine new employees, priced at $2.39 per share. This decision, finalized on October 27, 2022, was made in accordance with NASDAQ rules and as part of the newly adopted 2022 Inducement Equity Plan. The company is focused on developing advanced cell and gene therapies using its proprietary Gene Circuit platform to enhance treatment for various complex diseases, particularly in oncology.
Senti Bio announced two upcoming poster presentations at the Society for Immunotherapy of Cancer's 37th Annual Meeting, scheduled for November 10-12, 2022, in Boston. The presentations will focus on gene circuits to enhance CAR-NK cell therapy for treating solid tumors. Key topics include SENTI-401, which targets CEACAM5-expressing cancers, enhancing selectivity and efficacy. The event aims to showcase Senti Bio's innovative approach using its proprietary gene circuit platform to tackle significant oncology challenges.
Senti Biosciences, Inc. (Nasdaq: SNTI) announced participation by co-founder and CEO Tim Lu, CFO Deb Knobelman, and CMDO Kanya Rajangam in a Fireside Chat at Chardan’s 6th Annual Genetic Medicines Conference on October 3, 2022. Tim Lu will also join a panel on Gene Regulation on October 4, 2022. Live webcasts of the events will be available on Senti Bio's website for 120 days following the presentations. Senti Bio aims to develop innovative cell and gene therapies through its proprietary Gene Circuit platform.
Senti Biosciences, Inc. (Nasdaq: SNTI) announced participation in the Morgan Stanley 20th Annual Global Healthcare Conference on September 14, 2022, at 4:05 p.m. ET. Co-founder and CEO Tim Lu, CFO Deb Knobelman, and CMDO Kanya Rajangam will engage in a Fireside Chat during the event. A live webcast will be available on the Senti Bio Investors website for 180 days post-presentation. Senti Bio focuses on next-generation cell and gene therapies using their proprietary gene circuit platform to enhance treatment effectiveness for various diseases, including acute myeloid leukemia.
Chardan, a global investment bank, has launched its Chardan Equity Facility (ChEF), a new financing solution for public companies. The ChEF allows firms to raise equity periodically, bypassing traditional follow-on offerings. Senti Biosciences (SNTI) has secured a $50 million ChEF, while Dragonfly Energy (CNTQ) has announced a $150 million agreement. Chardan has raised over $30 billion for companies since its inception, including $10 billion for healthcare sectors, positioning itself as a vital partner for capital access in a challenging market.
Senti Biosciences (Nasdaq: SNTI) announced on August 19, 2022, that its compensation committee granted stock options to 35 new employees, totaling 421,659 shares at an exercise price of $1.99 each. This initiative is part of the Company's 2022 Inducement Equity Plan, adopted on August 5, 2022, to attract and retain talent. Senti Bio is focused on innovative cell and gene therapies using a proprietary gene circuit platform, particularly targeting oncology with several programs in development, including treatments for acute myeloid leukemia and hepatocellular carcinoma.
Senti Biosciences, Inc. (SNTI) reported a significant milestone with the selection of a lead development candidate from its SENTI-202 program, targeting acute myeloid leukemia (AML), with an IND filing expected in 2023. As of June 30, 2022, the company holds $139.8 million in cash, sufficient to support operations into 2024. However, R&D expenses increased to $9.2 million, and G&A expenses surged to $13.9 million, contributing to a net loss of $11.6 million for the second quarter, compared to $5.2 million and $4.6 million for the same quarter in 2021, respectively.